SEC Filing · 6-K
IceCure Medical Ltd.
ICCMNASDAQEQUITYCurrent
SEC Filing
Company context
IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, as a safe and effective minimally invasive option to surgical tumor removal, with the primary focus areas being breast, kidney, bone and lung cancer. The Company’s flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and Asia.
Current securities
As-filed source
As filedOpen full document ↗